Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion

Eye

Volumn 24, Issue 5, 2010, Pages 810-815

  Tao, Y ^a,b   Hou, J ^a   Jiang, Y R ^a   Li, X X ^a   Jonas, J B ^b  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Bevacizumab; Central retinal vein occlusion; Triamcinolone acetonide

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE ACETONIDE;

ADULT; ARTICLE; CENTRAL RETINA ARTERY OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; IRIS DISEASE; IRIS NEOVASCULARIZATION; MAJOR CLINICAL STUDY; MALE; RETINA MACULA EDEMA; VISUAL ACUITY; VITREOUS HEMORRHAGE;

EID: 77952517217     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2009.220     Document Type: Article

References (36)

1. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusions in Australia. The blue mountains eye study. Arch Ophthalmol 1996;114: 1243-1247. (Pubitemid 26338856)
2. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Ophthalmologica 2000;98: 113-143.
3. Liu W, Xu L, Jonas JB. Retinal vein occlusion Chinese subjects. Ophthalmology 2007;114: 1795-1796.
4. Hayreh SS. Classification of central retinal vein occlusion. Ophthalmology 1983;90: 458-474.
5. The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997;115: 486-491.
6. Jonas JB. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. Acta Ophthalmol 2005;83: 645-663.
7. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graef Arch Clin Exp Ophthalmol 2002;240: 782-783.
8. Holladay JT. Visual acuity measurements. J Cataract Refract Surg 2004;30: 287-290.
9. Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol 2002;86: 247-248.
10. Ip MS, Gottlieb JL, Kahana A, Scott IU, Altaweel MM, Blodi BA et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol 2004;122: 1131-1136.
11. Bashshur ZF, Ma'luf RN, Allam S, Jurdi FA, Haddad RS, Noureddin BN. Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Arch Ophthalmol 2004;122: 1137-1140.
12. Williamson TH, O'Donnell A. Intravitreal triamcinolone acetonide for cystoid macular edema in nonischemic central retinal vein occlusion. Am J Ophthalmol 2005;139: 860-866.
13. Cekiç O, Chang S, Tseng JJ, Barile GR, Del Priore LV, Weissman H et al. Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion. Retina 2005;25: 846-850. (Pubitemid 41456574)
14. Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide for treatment of central retinal vein occlusion. Eur J Ophthalmol 2005;15: 751-758. (Pubitemid 43074702)
15. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 2005;140: 695-702.
16. Ramezani A, Entezari M, Moradian S, Tabatabaei H, Kadkhodaei S. Intravitreal triamcinolone for acute central retinal vein occlusion; a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2006;244: 1601-1606.
17. Roth DB, Cukras C, Radhakrishnan R, Feuer WJ, Yarian DL, Green SN et al. Intravitreal triamcinolone acetonide injections in the treatment of retinal vein occlusions. Ophthalmic Surg Lasers Imaging 2008;39: 446-454.
18. Goff MJ, Jumper JM, Yang SS, Fu AD, Johnson RN, McDonald HR et al. Intravitreal triamcinolone acetonide treatment of macular edema associated with central retinal vein occlusion. Retina 2006;26: 896-901.
19. Gregori NZ, Rosenfeld PJ, Puliafito CA, Flynn Jr HW, Lee JE, Mavrofrides EC et al. One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. Retina 2006;26: 889-895.
20. Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 2005;140: 256-261.
21. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003;87: 24-27. (Pubitemid 36071773)
22. Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 2004;122: 336-340.
23. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 2004;138: 740-743.
24. Lau LI, Chen KC, Lee FL, Chen SJ, Ko YC, Liu CJ, Hsu WM. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection in a Chinese population. Am J Ophthalmol 2008;146: 573-578.
25. Gillies MC, Kuzniarz M, Craig J, Ball M, Luo W, Simpson JM. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 2005;112: 139-143.
26. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36: 336-339.
27. Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006;26: 279-284.
28. Spandau UH, Ihloff AK, Jonas JB. Intravitreal bevacizumab treatment of macular oedema due to central retinal vein occlusion. Acta Ophthalmol 2006;84: 555-556.
29. Hsu J, Kaiser RS, Sivalingam A, Abraham P, Fineman MS, Samuel MA et al. Intravitreal bevacizumab (avastin) in central retinal vein occlusion. Retina 2007;27: 1013-1019.
30. Priglinger SG, Wolf AH, Kreutzer TC, Kook D, Hofer A, Strauss RW et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina 2007;27: 1004-1012.
31. Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 2007;143: 601-606.
32. Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W et al. Intravitreal avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 2008;92: 518-522.
33. Moschos MM, Moschos M. Intraocular bevacizumab for macular edema due to CRVO. A multifocal-ERG and OCT study. Doc Ophthalmol 2008;116: 147-152.
34. Rensch F, Jonas JB, Spandau UH. Early intravitreal bevacizumab for non-ischemic central retinal vein occlusion. Acta Ophthalmol 2009;87: 77-81.
35. Wu WC, Cheng KC, Wu HJ. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion. Eye 2009. e-pub ahead of print 13 February 2009.
36. Jonas JB, Libondi T, Schlichtenbrede F, Schmidbauer M. Intravitreal triamcinolone after intravitreal bevacizumab for retinal vein occlusions. Acta Ophthalmol 2009. e-pub ahead of print 2 June 2009.